2020 SeraLabs New Product Info  

July 2020

CURE Pharmaceutical to Aquire CBD Leader Sera Labs in 20 Million Dollar Transaction 

OXNARD, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it has entered into a Memorandum of Understanding to acquire 100% of privately held Sera Labs for total up-front consideration of $20 million, comprising $19 million in CURE stock at a valuation of $2.75 per share, and $1 million in cash, with an initial, additional commitment of $4 million for working capital in support of accelerating Sera Labs’ growth. 

July 2020

Sera Labs working exclusive deal with Intl. manufacturer Oxygen Development for Sachet Program

Sera Labs rolls out 2ml packet dispensers with multiple retail ready counts as part of their overall PPE suite of products

July 2020

CURE Pharmaceutical’s (OTCMKTS:CURR) Pharmacokinetic Study On CBD Oral Thin Film Show Enhanced Bioavailability Relative to CBD Softgel

Vered Gigi, the Chief Scientific Officer of CURE Pharmaceutical, stated that according to results from a recent study, the CUREform™ technology enhances CBD bioavailability and thus helps lower the dose required. As a result, this will facilitate the minimization of the side effects and also improve compliance.